Medical research and drug development company headquartered in Cambridge, Massachusetts, specializing in gene therapies and antisense treatments for rare muscular dystrophies such as Duchenne muscular dystrophy.
Clinical Trials
131
71 active
Approvals
8
Total approvals
Agencies
1
Regulatory bodies
Founded
1980
Active, not recruiting
66
50.4%
Completed
24
18.3%
Enrolling By Invitation
2
1.5%
Not yet recruiting
3
2.3%
Recruiting
15
11.4%
Suspended
2
1.5%
Terminated
14
10.7%
Unknown
1
0.8%
Withdrawn
4
3.0%
- Novartis' Phase 3 HARBOR study of del-desiran failed to show statistically significant improvement over placebo on video hand opening time in myotonic dystrophy type 1. - The antibody oligonucleotide conjugate targets DMPK messenger RNA, and Novartis reported clinical activity on secondary endpoints and exploratory analyses including muscle strength. - Novartis shares fell about 9-10% while Dyne Therapeutics and Sarepta Therapeutics dropped sharply on read-through risk to their related DMPK programs. - Novartis is evaluating the full HARBOR dataset and will engage health authorities on a development path; no approved treatment exists for the disease itself.
- Advocates living with limb-girdle muscular dystrophy from more than 20 states held over 60 congressional meetings during The Speak Foundation's LGMD Day on the Hill. - The community is pressing for federal research investment, expanded Department of Defense funding access, and clearer regulatory pathways for rare-disease treatments. - Momentum is building around what could be the first FDA-approved LGMD therapy, a treatment for the LGMD 2I/R9 subtype developed by BridgeBio. - The Speak Foundation honored Reps. John Joyce and Jake Auchincloss with its 2026 Congressional Champion for Limb-Girdle Muscular Dystrophy Awards.
- BioGene Therapeutics has appointed Ty Howton, a nearly 30-year biopharmaceutical industry veteran, to its Board of Directors effective immediately. - Howton brings extensive experience scaling gene therapy and precision medicine companies from clinical to commercial stages, including leadership roles at Solid Biosciences, Sarepta Therapeutics, and Vertex Pharmaceuticals. - The appointment includes 100,000 stock options exercisable at $5.00 per share through June 2031 and 500,000 restricted share units, both vesting in 25% annual increments over four years. - BioGene is advancing gene therapies targeting metabolic health, including GLP-1 receptor agonists and treatments for diabetes and obesity through its Australian subsidiary.
- Acting FDA Commissioner Kyle Diamantas met with rare disease advocacy organizations on June 3 to rebuild trust following former Commissioner Marty Makary's tenure, which saw several setbacks for rare disease drugmakers. - Jeff Allen, CEO of Friends of Cancer Research, described the meeting as a "breath of fresh air" and praised Diamantas for exhibiting "real leadership" by listening to the rare disease community. - Advocacy groups pressed for greater regulatory clarity, novel clinical trial approaches, and consistency from the FDA for treatments targeting small patient populations. - The meeting comes as the White House reviews candidates for permanent FDA commissioner, with former commissioner Norman "Ned" Sharpless reportedly among those under consideration.
- The U.S. Patent and Trademark Office issued mixed decisions on Sarepta Therapeutics' patent challenges against Genzyme, denying institution of three inter partes review proceedings while granting one related to gene therapy analytical methods. - The patent disputes involve analytical ultracentrifugation and liquid chromatography/mass spectrometry methods for characterizing adeno-associated virus particles used in gene therapy products including Elevidys®. - These patent challenges are part of ongoing litigation between the companies, with Sarepta reporting $898.7 million in net revenue from Elevidys® in 2025.
- Gene therapy developers are increasingly exploring non-viral delivery methods following safety concerns with viral vectors, including patient deaths linked to liver toxicity in studies by Sarepta, Pfizer, Intellia, Rocket, and Capsida. - Lipid nanoparticles (LNPs), Sleeping Beauty transposon systems, and electro-transfection are emerging as promising non-viral alternatives that may offer improved safety profiles and reduced manufacturing complexity. - While experts view non-viral approaches as potentially representing the future of gene therapy, they expect these methods to coexist with viral vectors rather than completely replace them in the near term. - Non-viral systems offer advantages including greater payload flexibility, potentially lower manufacturing costs, and reduced immunogenicity risks, though further clinical validation is needed to realize their full potential.
- Moderna expects phase 3 data for norovirus and adjuvant melanoma programs in 2026, with the company up 82% year-to-date following a $2.25 billion patent settlement. - Krystal Biotech demonstrates strong fundamentals with 94% gross margins and $204 million net income in 2025, while advancing phase 3 trials in corneal DEB and neurotrophic keratitis. - Sarepta Therapeutics faces recovery challenges after ELEVIDYS revenue dropped 33% year-over-year due to safety-driven shipment suspensions, though management targets profitability return in 2026. - FDA regulatory environment under new leadership and potential staffing reductions could significantly impact approval timelines across the biotech sector.
- Sarepta Therapeutics plans to submit supplemental new drug applications by April 2026 to convert AMONDYS 45 and VYONDYS 53 from accelerated to traditional FDA approval for Duchenne muscular dystrophy treatment. - The ESSENCE confirmatory study showed numerical trends favoring treatment but missed statistical significance on the primary endpoint, though a COVID-adjusted analysis reached borderline significance (P=0.050). - Real-world evidence demonstrates substantial clinical benefits including 7.5-year delay in nighttime ventilation needs and multi-year delays in loss of ambulation for patients treated with these exon-skipping therapies. - The FDA has confirmed willingness to review both clinical trial data and real-world evidence as part of the supplemental applications for these therapies targeting ultra-rare genetic subgroups of DMD.
- NervGen Pharma appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP of Patient Advocacy and Clinical Affairs to advance their spinal cord injury treatment program. - Ruff brings over 30 years of regulatory expertise from companies including Stoke Therapeutics and Sarepta Therapeutics to guide NVG-291 toward potential approval as the first pharmacologic treatment for SCI. - McSherry, who founded the Jett Foundation after her son's Duchenne muscular dystrophy diagnosis, will ensure the SCI community's voice remains central to NervGen's clinical strategy. - The appointments strengthen NervGen's leadership as the company prepares for Phase 3 trials of NVG-291, which demonstrated durable improvements in function and quality of life in chronic SCI patients.
- BreezeBio, formerly GenEdit, secured $60 million in Series B funding to advance its proprietary NanoGalaxy delivery platform and internal therapeutic pipeline focused on autoimmune diseases and oncology. - The company's lead candidate BRZ-101 is designed to restore immune tolerance in type 1 diabetes by delivering autoantigens and tolerogenic co-factors to antigen-presenting cells, advancing into IND-enabling studies. - BreezeBio's NanoGalaxy platform demonstrates targeted delivery to immune, cardiac, pulmonary, and central nervous systems using specialized polymer nanoparticles that can be dosed multiple times. - The funding will support the company's transition from a delivery platform to a therapeutics company while continuing its collaboration with Genentech and expanding capabilities for in vivo CAR-T development.
